CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 9 enrolled
Drug / intervention
Niraparibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03497429
NCT03497429Phase 1Completed
CompareCT.gov

A Phase 1, Open-label Study of Niraparib as Single Agent in Patients With Advanced Solid Tumors

Takeda·interventional·Posted Apr 13, 2018·Updated Nov 9, 2021

In Brief

A Phase 1 clinical trial evaluating Niraparib for Advanced Solid Tumors. Completed, enrolled 9 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Niraparib in Japanese participants with advanced solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedApr 13, 2018
Enrollment StartApr 5, 2018
Primary CompletionFeb 10, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.2 years ago

Interventions

Niraparibdrug

Niraparib capsule